Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

CytomX Therapeutics Inc

CTMX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$3.36

▲ +0.30%

Market Cap $732.14M · Vol 499.00K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$732.14M

Small Cap

Div Yield

N/A

EPS Growth

-175.83%

YoY

RSI (14)

55.79

Momentum

Beta

2.13

vs Market

52W High

$8.20

59.02% below

52W Low

$1.78

88.76% above

Volume

499.00K

Avg 1.01M

P/B

7.32

Price-to-book

ROE

-35.25%

Return on equity

Free Float

94.75%

Public shares

Shariah Compliance8 STANDARDS

✗ CytomX Therapeutics Inc (CTMX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CTMX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.89%

-8.20%

-11.11%

-36.84%

YTD

-21.13%

+90.91%

+111.32%

-30.72%

Financials & Valuation

TTM · Annual

Total Revenue	$76.20M
Net Income	$-17,368,000.00
Revenue Growth (YoY)	-92.40%
Gross Margin	100.00%
Operating Margin	-25.15%
Net Profit Margin	-22.79%
ROE	-35.25%
ROA · ROIC	-12.59% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	7.71
P/B	7.32
P/FCF	N/A
EPS Growth	-175.83%
Outstanding Shares	217.90M

Technical Indicators

50-Day SMA	$3.36
200-Day SMA	$4.18
RSI (14)	55.79
Beta	2.13
52-Week High	$8.20
52-Week Low	$1.78

Volume Today	499.00K
Avg Daily Volume (30D)	1.01M
Relative Volume	0.50x
Volatility (10D)	34.13
Volatility (30D)	37.38
Free Float	94.75%

Analyst Consensus

STRONG BUY

Current Price $3.36

Mean Target $12.43

52W Low$1.78 52W High$8.20

Current

Target

$1.78 $8.20

Current Analyst target

+269.90% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V0GS49

ISINUS23284F1057

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.